within Pharmacolibrary.Drugs.ATC.A;

model A04AD13
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.35,
    Cl             = 0.0009166666666666666,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.3,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.013333333333333334,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.8,
    k12             = 140,
    k21             = 140
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A04AD13</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Casopitant is a neurokinin-1 (NK1) receptor antagonist that was developed for the prevention of chemotherapy-induced nausea and vomiting (CINV). Clinical development was discontinued and the drug is not currently approved for use in any country.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adult subjects following single oral administration. No published human PK model available; values estimated based on available summaries from clinical study result reports.</p><h4>References</h4><ol><li><p>Johnson, B, et al., &amp; Blum, R (2009). Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone. <i>Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer</i> 17(9) 1177–1185. DOI:<a href=&quot;https://doi.org/10.1007/s00520-008-0571-5&quot;>10.1007/s00520-008-0571-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19205755/&quot;>https://pubmed.ncbi.nlm.nih.gov/19205755</a></p></li><li><p>Dandamudi, UB, et al., &amp; Lewis, LD (2011). Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancer. <i>Cancer chemotherapy and pharmacology</i> 67(4) 783–790. DOI:<a href=&quot;https://doi.org/10.1007/s00280-010-1381-2&quot;>10.1007/s00280-010-1381-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20556613/&quot;>https://pubmed.ncbi.nlm.nih.gov/20556613</a></p></li><li><p>Adams, LM, et al., &amp; Stoltz, R (2009). Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron. <i>Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer</i> 17(9) 1187–1193. DOI:<a href=&quot;https://doi.org/10.1007/s00520-008-0572-4&quot;>10.1007/s00520-008-0572-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19205754/&quot;>https://pubmed.ncbi.nlm.nih.gov/19205754</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A04AD13;
